Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India’s Ozone Targets Five Half-Price Generics For Indian Market

This article was originally published in PharmAsia News

Executive Summary

Ozone Group says it plans to bring to India's market in July five drugs it will price at half the cost of what already is available. Ozone is one of a group of Indian pharmas seeking to counter an influx of questionable branded drugs into India by offering cheaper generics. Ozone's plans are focused on five drugs - an antibiotic and drugs to treat diarrhea, ulcers, pyretic and a painkiller. The firm's chairman and managing director. S.C. Sehgal, said the intent is to make available cheaper drugs with no sacrifice of quality, so he does not expect to garner major revenues from the drugs. (Click here for more

You may also be interested in...



UK Supplements Marketer Makes No Effort To Back Up Ad Claims

The UK's Advertising Standards Authority will closely monitor the marketing communications of dietary supplements e-tailer Health Solutions after it failed to provide a substantive response to health claims regulation breaches.

COVID-19: New Emergency Guidance From AAMI Targets Remote-Controlled Devices

Consensus report CR511 from the Association for the Advancement of Medical Instrumentation highlights common system elements for engineers, and outlines safety and risk-control measures that manufacturers and caregivers should consider.

Radical Shake-Up In Store For Entire EU Pharma Legislation

The EU pharmaceutical strategy published on 25 November will be the first step in a “complete overhaul” of the medicines legislative framework to be proposed in about two years’ time, says the European Commission.

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel